For prostate small cell carcinoma, INSM1 has been shown to be more sensitive (92.3%, 12/13) compared to SYP (84.6%, 11/13) and CgA (53.8%, 7/13), making it the superior NE marker for prostate small cell carcinoma. Here, INSM1 is linked to prostate small cell carcinoma.